益生菌对养老院居民抗生素使用的影响:一项随机临床试验
该安慰剂对照随机临床试验在英國23家养老院纳入310名65岁以上居民,比较每日口服鼠李糖乳杆菌GG与动物双歧杆菌乳亚种BB-12组合与安慰剂对全因感染抗生素累积使用天数的影响。结果显示两组抗生素使用天数无显著差异,不支持在该人群中使用益生菌。
要点
- 益生菌组与安慰剂组抗生素累积使用天数无显著差异。
- 研究结果不支持在养老院居民中使用益生菌。
核心结论
- 每日口服鼠李糖乳杆菌GG与动物双歧杆菌乳亚种BB-12组合未能显著减少养老院居民全因感染的抗生素使用。
- 这些发现不支持在该场景中使用益生菌。
研究设计与样本
- 研究为安慰剂对照随机临床试验,在英国23家养老院招募310名65岁及以上居民。
- 受试者随机接受每日益生菌胶囊(n=155)或匹配安慰剂(n=155),最长1年。
- 主要结局为随机化后1年内全因感染的累积抗生素使用天数。
主要发现
- 益生菌组平均累积抗生素使用天数为12.9天(95%CI 0-18.05),安慰剂组为12.0天(95%CI 0-16.95)。
- 共120名居民发生283起不良事件,益生菌组150起,安慰剂组133起。
关键数值与推荐
- 益生菌胶囊每粒总菌落数为1.3×10^10至1.6×10^10。
临床怎么用
- 对于养老院居民,不应常规使用该益生菌组合来减少抗生素使用。
局限性
- 仅62.9%的随机化居民存活并完成试验。
- 结果仅适用于所研究的特定益生菌组合和养老院人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Probiotics are frequently used by residents in care homes (residential homes or nursing homes that provide residents with 24-hour support for personal care or nursing care), although the evidence on whether probiotics prevent infections and reduce antibiotic use in these settings is limited. OBJECTIVE: To determine whether a daily oral probiotic combination of Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis BB-12 compared with placebo reduces antibiotic administration in care home residents. DESIGN, SETTING, AND PARTICIPANTS: Placebo-controlled randomized clinical trial of 310 care home residents, aged 65 years and older, recruited from 23 care homes in the United Kingdom between December 2016 and May 2018, with last follow-up on October 31, 2018. INTERVENTIONS: Study participants were randomized to receive a daily capsule containing a probiotic combination of Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis BB-12 (total cell count per capsule, 1.3 × 1010 to 1.6 × 1010) (n = 155), or daily matched placebo (n = 155), for up to 1 year. MAIN OUTCOMES AND MEASURES: The primary outcome was cumulative antibiotic administration days for all-cause infections measured from randomization for up to 1 year. RESULTS: Among 310 randomized care home residents (mean age, 85.3 years; 66.8% women), 195 (62.9%) remained alive and completed the trial. Participant diary data (daily data including study product use, antibiotic administration, and signs of infection) were available for 98.7% randomized to the probiotic group and 97.4% randomized to placebo. Care home residents randomized to the probiotic group had a mean of 12.9 cumulative systemic antibiotic administration days (95% CI, 0 to 18.05), and residents randomized to placebo had a mean of 12.0 days (95% CI, 0 to 16.95) (absolute difference, 0.9 days [95% CI, -3.25 to 5.05]; adjusted incidence rate ratio, 1.13 [95% CI, 0.79 to 1.63]; P = .50). A total of 120 care home residents experienced 283 adverse events (150 adverse events in the probiotic group and 133 in the placebo group). Hospitalizations accounted for 94 of the events in probiotic group and 78 events in the placebo group, and deaths accounted for 33 of the events in the probiotic group and 32 of the events in the placebo group. CONCLUSIONS AND RELEVANCE: Among care home residents in the United Kingdom, a daily dose of a probiotic combination of Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis BB-12 did not significantly reduce antibiotic administration for all-cause infections. These findings do not support the use of probiotics in this setting. TRIAL REGISTRATION: ISRCTN Identifier:16392920.
引用
- Butler CC, Lau M, Gillespie D, et al. Effect of Probiotic Use on Antibiotic Administration Among Care Home Residents: A Randomized Clinical Trial. JAMA. 2020. PMID: 32633801. doi:10.1001/jama.2020.8556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。